Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.59 |
| ▸ | HTR2C | P28335 | 8/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | CHUK | O15111 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21636393 | 0.90 | SLC6A4 (0.69) | SLC6A4HTR2CADRB2DYRK1AOPRM1 | |
| SCHEMBL21636296 | 0.87 | SLC6A4 (0.62) | SLC6A4HTR2CADRB2DYRK1AOPRM1 | |
| SCHEMBL6812169 | 0.83 | HTR2C (0.59) | SLC6A4HTR2CADRB2IKBKBCHUK | |
| SCHEMBL653733 | 0.81 | SLC6A4 (0.59) | SLC6A4HTR2CADRB2IKBKBCHUK | |
| SCHEMBL30832683 | 0.81 | HTR2C (0.58) | SLC6A4HTR2CADRB2IKBKBCHUK | |
| SCHEMBL6782459 | 0.81 | HTR2C (0.58) | SLC6A4HTR2CADRB2IKBKBCHUK | |
| Hydrochloric Acid SCHEMBL7866378 | 0.80 | HTR2C (0.59) | SLC6A4HTR2CADRB2IKBKBCHUK | |
| SCHEMBL21624161 | 0.78 | SLC6A4 (0.55) | SLC6A4HTR2CADRB2DYRK1AOPRM1 | |
| SCHEMBL6087789 | 0.78 | SLC6A4 (0.55) | SLC6A4HTR2CADRB2IKBKBDYRK1A | |
| SCHEMBL8723523 | 0.78 | HTR2C (0.54) | SLC6A4HTR2CADRB2IKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183251-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2004-02-11 | — | — | EP | disclosed |
| US-6683096-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-01-27 | — | — | US | disclosed |
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | SLC6A4 445/4885HTR2C 32/4885ADRB2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.